Skip to main content
. Author manuscript; available in PMC: 2024 Jan 14.
Published in final edited form as: Mol Cancer Res. 2020 Apr 29;18(8):1202–1217. doi: 10.1158/1541-7786.MCR-19-1162

Figure 6. Functional rescue experiments to test if BAG5 and SPARC are direct downstream effectors of miR-4454.

Figure 6.

Kuramochi cells were transfected with anti-miR-4454/BAG5-siRNA/SPARC-siRNA or both anti-miR-4454 and siRNA or scrambled control oligos (Scr). The transfected cells were then used for the functional assays. (A) Migration: Transfected cells were seeded in transwell inserts with 8 μm pores in and allowed to migrate towards medium containing 10% FBS. Migrated cells were fixed, imaged and quantified using image-J software (mean ± SD; 3 independents experiments). (B) Transfected cells were seeded in 96-wella plates and allowed to grow for 5 days. Cell proliferation was determined by MTT assay (mean ± SD; 3 independents experiments). (C) Colony formation: Transfected cells were seeded in 6-well plates and allowed to form colonies. Colonies were fixed after 2–3 weeks, stained (0.005% crystal violet) and counted using image-J software (mean ± SD; 3 independents experiments). * p<0.01, Students t-test. (D) Kaplan–Meier plot for effect of BAG5 (Affy ID:202985_s_at) and SPARC (Affy ID: 212667_at) expression levels on 5-year progression free survival in ovarian cancer patients using KM Plotter. Red: High expression; Black: Low expression.